Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

LGD-4033 and Methylene Blue Interaction: Avoid | Peptide Database

Compound Profiles LGD-4033 Selective Androgen Receptor Modulator | Lean Mass LGD-4033 binds to the androgen receptor with high affinity (Ki of approximately 1 nM), functioning as a potent and selective agonist in muscle and bone tissue. Like other SARMs, its t

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Compound Profiles

LGD-4033

Selective Androgen Receptor Modulator | Lean Mass

LGD-4033 binds to the androgen receptor with high affinity (Ki of approximately 1 nM), functioning as a potent and selective agonist in muscle and bone tissue. Like other SARMs, its tissue selectivity is mediated by differential cofactor recruitment: upon binding to the AR, LGD-4033 induces a receptor conformation that preferentially recruits coactivators expressed in skeletal muscle and bone, while showing minimal agonist activity in androgen-sensitive tissues such as the prostate and skin.

Methylene Blue

Mitochondrial Electron Carrier | Cognitive & Neuroprotection

Methylene blue functions as a redox cycling agent in mitochondria. In its oxidized form, it accepts electrons from NADH through Complex I and is reduced to leucomethylene blue.

Combined Organ Load

Shared Safety Flags

Frequently Asked Questions

Can I take LGD-4033 with Methylene Blue?

Combining LGD-4033 with Methylene Blue is not recommended. Both LGD-4033 and Methylene Blue carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is LGD-4033 and Methylene Blue safe together?

This combination carries significant risk. Both LGD-4033 and Methylene Blue carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between LGD-4033 and Methylene Blue?

Both LGD-4033 and Methylene Blue carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 64% confidence and is inferred from pharmacological mechanism analysis.

How should I time LGD-4033 and Methylene Blue?

LGD-4033 has a half-life of ~24-36 hours and Methylene Blue has a half-life of ~5-6 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

comparison

BPC-157 vs TB-500: Mechanisms, Dosing & the Wolverine Stack

How BPC-157 and TB-500 compare for healing: mechanism differences, dosing protocols, clinical evidence, and when to combine both in the Wolverine Stack.

Source: peptide-db.com
comparison

What's the dose range for cognitive enhancement versus being too much?

The cognitive 'sweet spot' is 0.5-2 mg/kg body weight (roughly 35-140 mg for a 70 kg person). Doses above 2 mg/kg often shift from antioxidant to pro-oxidant effects, becoming counterproduc…

Source: peptide-db.com
comparison

What's the addiction risk of phenibut vs benzodiazepines?

Phenibut carries similar addiction and withdrawal risk to benzodiazepines despite not being a benzo. Physical dependence can develop in as little as 1-2 weeks of daily use, and withdrawal i…

Source: peptide-db.com
Research context

Read sources and limitations before applying a claim.

Research Indications

Directly activates the master metabolic regulator through ZMP accumulation. Increases fat burning through AMPK-mediated pathways. Enhances glucose uptake independent of insulin in some tissues. Animal studies showed increased running endurance; human data limited. AMPK activation promotes new mitochondria formation over time. Original clinical interest; may protect heart tissue during reduced blood flow.

Source: peptide-db.com ↗

Why does 2024 research show BAM-15 works better with semaglutide?

Combining BAM-15 (mitochondrial uncoupler) with semaglutide (GLP-1 agonist) produces stronger metabolic benefits than either alone by countering metabolic adaptation. Semaglutide's appetite suppression plateaus as the body adapts; BAM-15's energy expenditure boost prevents this adaptation, allowing sustained weight loss.

Source: peptide-db.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

Dosing Protocols

Available in capsule form for oral administration. As a tripeptide, Ovagen is transported via PEPT1/PEPT2 transporters for targeted delivery to liver and GI tissue. Typical protocol involves 10-20 day cycles. Standard protocol 10-20 mg Daily for 10-20 days Oral capsules Maintenance 10 mg 2-3 cycles yearly

Source: peptide-db.com ↗
Potential benefits

What are the cardiovascular benefits of B7-33 compared to other compounds?

B7-33 reduces myocardial fibrosis, enhances vasodilation through nitric oxide pathway, and demonstrates cardioprotective effects in heart failure models. These anti-fibrotic and vasoprotective properties position it for potential use in cardiac remodeling, though all current data is preclinical.

Source: peptide-db.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →